| 0000-00-00 |
|
|
|
External link to document |
| 2018-12-10 |
1 |
Complaint |
(“the ’797 patent”); and
10,010,533 (“the ’533 patent”) (collectively, “the Patents-in-Suit”).
…COUNT IV – INFRINGEMENT OF U.S. PATENT
NO. 10,010,533 UNDER 35 U.S.C. § 271(e)(2)
… INFRINGEMENT OF U.S. PATENT NO. 10,010,533
94. Eagle incorporates…infringement of the ’831 patent, the ’796 patent, the ’797 patent, and the ’533
patent.
(b…of Eagle’s U.S. Patent Nos.
9,265,831 (“the ’831 patent”); 9,572,796 (“the ’796 patent”); 9,572,797 (“ |
External link to document |
| 2019-01-10 |
17 |
Redacted Document |
(“the
‘797 patent”); and 10,010,533 (“the ‘533 patent”) (collectively, the “patents-in-suit”), which
…infringes
U.S. Patent Nos. 9,265,831 (“the ‘831 patent”); 9,572,796 (“the ‘796 patent”); 9,572,797 (“… the patents-in-suit. Rather, Plaintiff’s complaint alleges
that Slayback infringes the patents-in-suit…infringe any claim of the patents-in-suit. All of the independent claims of these patents require a
pharmaceutically…equivalents to prove infringement of
the patents-in-suit. “[W]hen a patent drafter discloses but declines to |
External link to document |
| 2019-02-11 |
23 |
Redacted Document |
“’831
Patent”); 9,572,796 (the “’796 Patent”); 9,572,797 (the “’797 Patent”); and 10,010,533 (the “’… four patents listed in the
Orange Book and covering the formulation of Belrapzo®. U.S. Patents 9,265,831…“’533
Patent”) (the “Patents-in-Suit”) list inventors Nagesh Palepu and Philip Buxton. Certain claims…Plaintiff Plausibly Pled that Slayback Infringes the Patents-in-Suit............8
3. …
questions over the proper interpretation of a patent’s intrinsic record are “not suitable” and
“particularly |
External link to document |
| 2019-05-09 |
28 |
Memorandum Opinion |
the "#796 patent"),
9,572,797 (the "#797 patent"), and 10,010,533 (the "#533…equivalents of four patents: U.S.
Patent Nos. 9,265,831 (the "#831 patent"), 9,572,796 …glycol in embodiments of the
patented invention. See, e.g., #796 patent at 1:60-64, 4:34-47, 5:27-35,…;#533 patent"). See generally
D.I. 1. Pending before me is Slayback's motion for judgment…manufacture and sell before the four
asserted patents expire a bendamustine drug that is bioequivalent |
External link to document |
| 2019-05-09 |
30 |
Patent/Trademark Report to Commissioner |
;9,572,796 B2 ;9,572,797 B2 ;10,010,533 B2. (Attachments: # 1 Order granting Motion for Judgment on the… Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 9,265,831 B2 ;…December 2018
9 May 2019
1:18-cv-01953
835 Patent - Abbreviated New Drug Application(ANDA)
None |
External link to document |
| 2019-05-09 |
31 |
Memorandum Opinion |
the "#796 patent"),
9,572,797 (the "#797 patent"), and 10,010,533 (the "#533…equivalents of four patents: U.S.
Patent Nos. 9,265,831 (the "#831 patent"), 9,572,796 …glycol in
embodiments of the patented invention. See, e.g., #796 patent at 1 :60-64, 4:34-47,
5:27-35…;#533 patent"). See generally
D.I. 1. Pending before me is Slayback's motion for judgment …manufacture and sell before the four
asserted patents expire a bendamustine drug that is bioequivalent |
External link to document |
